Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75976

UPID:
CBPD_HUMAN

ALTERNATIVE NAMES:
Metallocarboxypeptidase D; gp180

ALTERNATIVE UPACC:
O75976; B7Z7T9; B7ZAU4; F5GZH6; O15377; Q86SH9; Q86XE6

BACKGROUND:
The enzyme Carboxypeptidase D, recognized by its alternative names Metallocarboxypeptidase D and gp180, is integral to the maturation and degradation of proteins. By removing amino acids from the ends of peptides, it ensures proteins achieve their functional conformations, highlighting its significance in cellular biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Carboxypeptidase D holds promise for uncovering novel therapeutic approaches. Given its involvement in protein processing, targeting this enzyme could lead to breakthroughs in managing conditions associated with abnormal protein metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.